Triple Agonist for Research Use
Retatrutide 15mg
Retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon receptors. Published trial data reports the largest mean bodyweight reductions of any incretin studied to date.
Appetite
Control
Fat Loss
Acceleration
Metabolic
Optimization
Glucose
Regulation
Why Researchers Use It
Highlights
- ✓ Triple receptor agonism (GIP / GLP-1 / glucagon)
- ✓ Marked appetite suppression in published trials
- ✓ Increased energy expenditure via glucagon signalling
- ✓ Improved glycaemic markers
- ✓ Weekly administration schedule in trial protocols
Research Background
Retatrutide (LY3437943) is a 39-amino-acid peptide with a C20 fatty di-acid moiety enabling weekly dosing. Phase 2 literature reports mean bodyweight reduction of up to 24.2% at 48 weeks.
Reference Range In Literature
Laboratory reference range in published trials: titrated from 1mg weekly upward. For research use only.
Storage & Handling
Store at 2-8°C. After reconstitution refrigerate and use within 30 days. Do not freeze.
Bundle & Save
Included In These Protocols
Buying this compound as part of a stack is cheaper than buying it alone, and every stack ships with the bacteriostatic water you need.
Questions
Frequently Asked
Verified Buyers
Researcher Reviews
Best in class
Tried the other incretins. This is a different level. Appreciate that the batch COA is public.
Keep Looking
Other Compounds
20mg
BPC-157 20mg
Peptide for Research Use
Starting at
$50
20mg
TB-500 20mg
Peptide for Research Use
Starting at
$70
100mg
GHK-CU 100mg
Copper Peptide for Research Use
Starting at
$65
10mg / 10mg
CJC-1295 (no DAC) + Ipamorelin 10mg / 10mg
Blended Peptide for Research Use
Starting at
$60